London pre-open: No sign of Wall St. hangover
25th Jun 2010 07:43
After the Dow Jones suffered a triple-digit fall overnight there were fears that London might go the same way, but traders are predicting the FTSE 100 will open a little higher, up 16 points at 5,116. BP has spent another $350,000 (£234,000) on the Gulf of Mexico oil disaster since Monday, taking t
Read moreAstraZeneca: FDA Resets Review Date For Motavizumab To Aug 27
25th Jun 2010 07:11
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN), a global biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines, said Friday its biologics unit MedImmune received notice that the U.S. Food and Drug Administration has reset the deci
Read moreFDA resets review date for Astra drug
25th Jun 2010 07:04
Anglo-Swedish drugs group AstraZeneca said the US Food and Drug Administration (FDA) has reset the decision date for its review of Astra's respiratory disease treatment, motavizumab. The date has been reset to 27 August 2010. Motavizumab was reviewed by the FDA's Antiviral Drugs Advisory Committe
Read moreBroker tips: Glaxo, Micro Focus, DSG
24th Jun 2010 13:00
If GlaxoSmithKline pulls the trigger and launches its Lucozade brand in the US, it could be the key to unlocking shareholder value and rectify the stock's underperformance relative to fellow pharmaceuticals giant AstraZeneca, Panmure Gordon reckons. The size of the US market for soft drinks is arou
Read morePfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
24th Jun 2010 12:36
(This article was originally published Wednesday.) By Thomas Gryta and Peter Loftus Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controve
Read moreN AMERICAN MORNING BRIEFING: Recovery Fears To Hit Stocks
24th Jun 2010 11:44
DJIA Futures 10191.50 -33.50 -0.30% S&P 500 Futures 1081.60 -5.80 -0.50% Nasdaq Futures 1860.13 -13.63 -0.70% Above are as of 0615 ET FTSE 100 5144.85 -33.67 -0.70% Xetra DAX 6160.65 -43.87 -0.70% CAC40 3602.90 -38.89 -1.10% Above are as of 0
Read moreN AMERICAN MORNING BRIEFING: Recovery Fears To Hit Stocks
24th Jun 2010 11:43
DJIA Futures 10191.50 -33.50 -0.30% S&P 500 Futures 1081.60 -5.80 -0.50% Nasdaq Futures 1860.13 -13.63 -0.70% Above are as of 0615 ET FTSE 100 5144.85 -33.67 -0.70% Xetra DAX 6160.65 -43.87 -0.70% CAC40 3602.90 -38.89 -1.10% Above are as of 0
Read moreAstraZeneca Buys Back 610,000 Shares For Cancellation
24th Jun 2010 08:30
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Thursday it has purchased for cancellation 610,000 of its ordinary shares at a price of 2997 pence per share. MAIN FACTS: -Shares at 0730 GMT up 4.5 pence, or 0.2%, at 3001 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-92
Read moreBMS's Diabetes Drug Dapagliflozin Shows Promise - Lancet
24th Jun 2010 00:01
LONDON (Dow Jones)--Bristol-Myers Squibb Co.'s (BMY) new drug for treating Type-2 diabetes, dapagliflozin, could be considered as a new therapeutic option for patients who have inadequate blood sugar control with first-line drug metformin, and also for early-stage and late-stage diabetes, researcher
Read moreUPDATE:Pfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
23rd Jun 2010 22:56
(Adds details on company's reason for ending the study beginning in fourth paragraph.) By Thomas Gryta and Peter Loftus Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in childre
Read morePfizer Ends Pediatric Bipolar-Drug Trial Before It Starts
23rd Jun 2010 22:40
By Thomas Gryta and Peter Loftus of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controversial area for the drug. The New York-based pharmaceut
Read moreAstraZeneca Buys Back 500,000 Shares At 3041P
23rd Jun 2010 08:06
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Wednesday it has purchased for cancellation 500,000 of its ordinary shares at a price of 3041 pence per share. MAIN FACTS: -Shares at 0705 GMT down 24 pence, or 0.8%, at 3024 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-
Read morePRESS RELEASE: Dapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naive Adults with Type 2 Diabetes
22nd Jun 2010 15:00
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--June 22, 2010-- Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant me
Read morePRESS RELEASE: Dapagliflozin as Monotherapy -2-
22nd Jun 2010 15:00
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors th
Read moreBEFORE THE BELL-2: US HOT STOCKS TO WATCH
21st Jun 2010 13:40
Among the companies expected to actively trade in Monday's session are Anadarko Petroleum Corp. (APC), BP PLC (BP, BP.LN) and American Italian Pasta Co. (AIPC). Anadarko late Friday called the oil spill in the Gulf of Mexico "preventable and the direct result of BP's reckless decisions and acti
Read more